Haemonetics (STU:HAZ) ROCE %: -4.56% (As of Mar. 2026)

What is Haemonetics ROCE %?

Haemonetics STU:HAZ 25 ROCE % is -4.56% as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 25/100 and a GF Value™ of €74.16. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Haemonetics's annualized ROCE % for the quarter that ended in Mar. 2026 was -4.56%.

Haemonetics (STU:HAZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Haemonetics ROCE % Related Terms

Haemonetics ROCE % Historical Data

* Premium members only.

The historical data trend for Haemonetics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics ROCE % Chart

Haemonetics Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

5.63

10.19

9.15

11.81

7.62

Haemonetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															13.51	10.97	12.13	14.04	-4.56

25GF Score

Haemonetics Corp STU:HAZ

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Haemonetics ROCE % Calculation

Haemonetics's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	135.575	/	( ( (2267.127 - 534.755)	+	(2072.475 - 244.448) )	/ 2 )
	=	135.575	/	( (1732.372	+	1828.027)	/ 2 )
	=	135.575	/	1780.1995
	=	7.62 %

Haemonetics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-79.668	/	( ( (2127.22 - 461.047)	+	(2072.475 - 244.448) )	/ 2 )
	=	-79.668	/	( ( 1666.173	+	1828.027 )	/ 2 )
	=	-79.668	/	1747.1
	=	-4.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -4.56% mean?

Haemonetics (STU:HAZ) has a ROCE % of -4.56% as of Mar. 2026.

Is Haemonetics' ROCE % too high?

Haemonetics' current ROCE % is -4.56%. Overall, Haemonetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does Haemonetics' ROCE % compare to ITGR and IRTC?

Haemonetics' ROCE % of -4.56% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current ROCE % is -4.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Haemonetics stock overvalued right now?

Haemonetics (STU:HAZ) has a current ROCE % of -4.56%. The stock's GF Value™ is €74.16, compared to a current price of €65.50 — trading 11.7% below its estimated fair value. The current ROCE % is -4.56%. Haemonetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current ROCE % is -4.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.

Key valuation signals for STU:HAZ:

ROCE %: -4.56%
GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ITGR IRTC ESTA LIVN AXGN TMDX BFLY NEOG UFPT ALMR ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges HAE:USA

Address 125 Summer Street, Boston, MA, USA, 02110

Website https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

25GF Score

Get the complete analysis for STU:HAZ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50

Price

€74.16

GF Value

View STU:HAZ Analysis

See ROCE % data for all stocks →